TABLE 2.

Susceptibilities of patient HIV-1 recombinant isolates to protease inhibitors

Isolate	Insertion	Major protease inhibitor mutation(s)	Recombinantb	IC50 (μM)a
				IDV	SQV	NFV
NL4-3			Wild type	0.02 ± 0.02	0.01 ± 0.00	0.02 ± 0.01
Q058	35TVLEE	I54V, L90M	Insertion	0.52 ± 0.04 (22.2)	0.16 ± 0.07 (16.5)	0.13 ± 0.03 (5.7)
			Deletion	0.09 ± 0.08 (3.9)	0.10 ± 0.10 (10.2)	0.15 ± 0.02 (6.8)
Q781	36NL	None	Insertion	0.05 ± 0.01 (2.0)	0.03 ± 0.03 (2.8)	0.03 ± 0.04 (1.5)
			Deletion	0.02 ± 0.00 (0.7)	0.00 ± 0.00 (0.5)	0.01 ± 0.01 (0.5)
U099	35TD	None	Insertion	0.02 ± 0.02 (0.7)	0.00 ± 0.00 (0.2)	0.04 ± 0.02 (1.6)
			Deletion	0.03 ± 0.02 (1.2)	0.00 ± 0.00 (0.5)	0.02 ± 0.03 (1.0)
Q164	36NL	V82A	Insertion	0.06 ± 0.02 (2.6)	0.01 ± 0.02 (1.4)	0.04 ± 0.02 (1.6)
			Deletion	0.02 ± 0.00 (0.7)	0.02 ± 0.01 (1.6)	0.06 ± 0.06 (2.9)
Q822	37D	None	Insertion	0.01 ± 0.02 (0.6)	0.04 ± 0.04 (3.8)	0.04 ± 0.02 (1.9)
			Deletion	0.04 ± 0.00 (1.6)	0.01 ± 0.01 (0.8)	0.01 ± 0.00 (0.4)
Q650	36NL	None	Insertion	0.01 ± 0.00 (0.2)	0.01 ± 0.00 (0.9)	0.01 ± 0.00 (0.3)
Q552	36NL	None	Insertion	0.01 ± 0.01 (0.4)	0.01 ± 0.00 (0.6)	0.01 ± 0.00 (0.4)
Q645	36GL	L10I, I84V	Insertion	0.02 ± 0.00 (0.8)	0.03 ± 0.01 (3.5)	0.02 ± 0.00 (0.9)
Q288	35TN	I84V, L90M	Insertion	0.03 ± 0.01 (1.2)	0.07 ± 0.06 (7.3)	0.10 ± 0.07 (4.5)
V493	36DL	L10I, M46I, I54V, I84V	Insertion	0.27 ± 0.33 (6.0)	1.21 ± 1.64 (45.2)	0.30 ± 0.38 (13.6)
Q008	17R	L46I, L90M	Insertion	0.11 ± 0.12 (4.6)	0.09 ± 0.03 (9.3)	0.28 ± 0.06 (8.2)
Q804	95TLNFPI	L10I, L90M	Insertion	0.16 ± 0.12 (6.8)	0.06 ± 0.05 (6.2)	0.12 ± 0.09 (5.2)

^aIC₅₀s are the means of results of three to four tests. Recombinant isolates were prepared and tested as described in the text. Values in parentheses are fold changes in IC₅₀s relative to that of the wild type. 

^b“Wild type” represents a recombinant virus containing an NL4-3 PR gene.